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Abstract 
The impact of BCR-ABL mRNA type (b3a2
vs. b2a2) on chronic myeloid leukemia (CML)
phenotype is still a subject of controversies. We
searched for a correlation between the BCR-
ABL transcripts type and CML patients’ charac-
teristics,  including  MDR1 gene  expression.
Ninety-eight  untreated  chronic  phase  CML
patients were studied. The type of BCR-ABL
fusion transcripts and MDR1 gene expression
were determined by reverse transcriptase poly-
merase chain reaction. B3a2 and b2a2 tran-
scripts were found in 53 [54%] and 44 [45%]
patients,  respectively.  One  patient  co-
expressed b3a2/b2a2 and was excluded from
analysis.  The  only  difference  in  the  clinical
characteristics  between  the  two  groups  was
the platelets count, that was higher in b3a2(+)
patients [791.3±441.3ﾥ109/L vs. 440.4±283.4ﾥ
109/L in b2a2(+); P=0.007]. MDR1 over-expres-
sion [MDR1(+)] was observed in 48 patients
(49.5%), more frequently in older patients >60
years [71% (24/34) vs. 38% (24/63) in younger;
P=0.008],  and  was  associated  with  a  lower
white blood cells (WBC) count [105.5±79.8ﾥ
109/L vs. 143.6±96.5ﾥ109/L in MDR1(–) cases;
P=0.047].  On  performing  the  analysis  only
within  the  MDR1(+) group,  the  b3a2
(+) cases
were characterized with a significantly higher
platelets  count  [908.7±470.1ﾥ109/L  vs.
472.9±356.1ﾥ109/L; P=0.006] and a lower WBC
count  [85.4±61.2ﾥ109/L  vs.  130±93.9ﾥ109/L;
P=0.004)  compared  to  b2a2(+)  patients.  No
similar  differences  were  found  between
b3a2(+) and b2a2(+) groups with normal MDR1
levels. These results indicate that the type of
BCR-ABL transcripts correlates with the hema-
tological parameters of CML, however only in
the  subgroup  of  patients  characterized  by
MDR1 over-expression. 
Introduction
Chronic myeloid leukemia (CML) is charac-
terized by the consistent involvement of the
Philadelphia chromosome (Ph) and the BCR-
ABL fusion gene, which derives from the recip-
rocal  translocation  t(9;22)(q34;q11)  between
chromosome  9  and  22.  In  almost  all  CML
patients,  the  breakpoint  in  the  BCR gene
involves the Major breakpoint cluster region
(M-bcr). The position of the breakpoint within
the M-bcr, after exon b2 (e13) or exon b3 (e14)
determines two main types of the fused BCR-
ABL mRNA  defined  as  b2a2  and  b3a2  tran-
scripts differing by 75 nucleotides. These tran-
scripts  encode  two  210-kDa  tyrosine  kinase
proteins  (p210BCR-ABL),  which  differ  by  25
amino acids respectively.1
The impact of M-bcr breakpoint position on
disease phenotype and its prognosis has been
a  subject  of  controversies  for  a  long  time.
Several reports have suggested that the type of
the chimeric mRNA (b2a2 or b3a2) is associat-
ed with differences in the clinical and hemato-
logical  characteristics  of  CML  patients  and
prognosis, despite that others failed to confirm
any significant correlation.2-6 One of the most
interesting finding is the association of b3a2
type of fusion transcript with a higher platelet
counts  with  some  evidence  in  favor7-9 and
some against.10-12 A great deal of the discrep-
ancy or discordance between the various stud-
ies could be due to qualitative and/or quantita-
tive  differences  in  patient  or  sample  selec-
tion.12 However,  the  contradictory  results
might  also  be  attributed  to  the  presence  of
unknown biological factors, which can affect
the obtained results. This hypothesis is sup-
ported  by  the  observation  of  Shepherd  et
al.,1995  who  failed  to  detect  any  significant
difference in the presented features at diagno-
sis for patients with either b2a2 or b3a2 tran-
scripts.  However,  in  a  subgroup  of  patients
whose  presenting  white  blood  cell  (WBC)
count was <100ﾥ109/L, those with b3a2 tran-
script did have a significantly higher platelet
count.13 On the other hand, it has been report-
ed that early chronic phase CML patients with
very similar characteristics (i.e. thrombocyto-
sis, WBC count <50ﾥ109/L, and age >50 years)
were  characterized  with  elevated  levels  of
Multidrug Resistance 1 (MDR1) gene expres-
sion.14 Therefore, it might be possible, that the
level of MDR1 gene expression in the individ-
ual CML patients could influence the associa-
tion  between  the  different  BCR-ABL tran-
scripts and disease features.
MDR1 gene, located on chromosome 7q21
encodes a 170 kD membrane transporter P-gly-
coprotein  [P-gp]  that  acts  as  an  energy-
dependent,  efflux  pump.  Over-expression  of
MDR1/P-gp confers resistance to the cytotoxic
effects of a broad range of structurally unrelat-
ed  compounds  (i.e.  anthracyclines,  epipodo  -
phyllotoxins and vinca alkaloids) and is one of
the  most  common  mechanisms  of  so-called
multidrug resistance (MDR) in various malig-
nancies.  Over-expression  of  the  MDR1 gene
has been found in a significant proportion of
patients  with  different  hematological  malig-
nancies and several observations suggest its
poor prognostic value.15
The data concerning the incidence of MDR1
over-expression in chronic phase CML patients
are controversial ranging from total absence to
presence  in  20-65%  and  up  to  in  100%  of
patients.14,16-20 Even less is known about the
relationship of the MDR1 levels to clinical data
at  presentation  in  CML.14 The  association
between the MDR1 levels and type of BCR-ABL
transcripts  to  our  knowledge  has  not  been
studied yet.
In  this  study  we  analyzed  the  correlations
between  the  BCR-ABL mRNA  types  and  CML
patients’ characteristics at presentation, includ-
ing the possible impact of MDR1 mRNA levels.
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Materials and Methods
Patients
Ninety-eight untreated consecutive chronic
phase CML patients (59 males and 39 females)
with a mean age 50.5±14.1 years were includ-
ed in this study. All patients signed informed
consent form before entry on study. The diag-
nosis of CML was established on the basis of
the peripheral blood parameters and morpho-
logical analysis of peripheral blood and bone
marrow aspirates and confirmed by the pres-
ence  of  Philadelphia  chromosome  and/or
fusion BCR-ABL gene by conventional cytoge-
netics  and  reverse  transcription  polymerase
chain reaction (RT-PCR) respectively.
Methods
RNA extraction and complementary DNA
(cDNA) synthesis
Bone marrow and/or peripheral blood sam-
ples were collected after obtaining informed
consent  at  the  time  of  CML  diagnosis.
Mononuclear cells were separated after lysis of
red  blood  cells  with  a  lysis  buffer  (155  mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA).21 Total
cellular RNA was isolated using Trizol Reagent
(Invitrogen) according to the manufacturer’s
protocol.  cDNA  was  synthesized  by  reverse
transcription  of  1  ʼg  of  RNA  in  a  reaction
medium with final volume of 20 ʼl containing:
1x  first-strand  buffer,  200  U  MMLV  reverse
transcriptase  (Thermo  Scientific,  ABGene,
UK),  1  mM  of  each  dNTPs,  20  U  RNAsin
(Promega)  and  5  ʼM  random  hexamers
(Roche Diagnostics), by consecutive incuba-
tion of the samples at 37°C for 1 hour and at
99°C for 3 minutes. Random hexamers instead
of specific primers were used so that different
PCR analyses could be performed on the same
cDNA sample. 
PCR assay for BCR-ABL
The presence of P210BCR-ABL rearrangement
and  the  type  of  the  respective  fusion  tran-
scripts were determined by a single step RT-
PCR using primers (ABL-a3B: gtttgggcttcacac-
cattcc/BCR-b1A:  gaagtgtttcagaagcttctcc)  and
according to the protocol, recommended by the
European  BIOMED  1  Concerted  Action  for
standardization  of  MRD  studies  in  acute
leukaemia.22 Briefly, 5 ʼL of cDNA were ampli-
fied in a 50 ʼL medium containing 1x PCR
buffer, 2.5 mM MgCl2, 200 ʼM each of dNTPs,
1 U Taq polymerase (Invitrogen), and 400 nM
of each of upstream and downstream primers.
The mixture was incubated at 94°C for 30 sec;
65°C for 60 sec; 72°C for 60 sec with a total 35
cycles  using  Mastercycler  Gradient
(Eppendorf). Amplification products were run
in a 2% agarose gel (Invitrogene) after stain-
ing with ethidium bromide, visualized after UV
irradiation and photographed. For all RT-PCR
reactions, K562 (b3a2) and/or BV173 (b2a2)
cell lines were used as a positive control and
RNA from healthy donors as a negative control. 
PCR assay for MDR1 gene expression 
PCR was carried-out by simultaneous ampli-
fication  of  the  MDR1 and  β2-microglobulin
(β2-M) RNA, as an internal control. Briefly, 5
ʼl of cDNA were amplified in 50 ʼL medium,
containing 1x PCR buffer, 1.5 mM MgCl2; 200
ʼM  each  of  dNTPs;  1  U  Taq  polymerase
(Promega) and 0.4 pM each of primers MDR1-
TL9: ttcaaacttgtcacaatgcaga cagcagga / MDR1-
TL10:  ggttgcaggcctccatttataatggcacaa  (for
MDR1);  together  with  B2-M1:  acccccact-
gaaaaagatga/B2-M2:  atcttcaaacctccatgatg
primers (for β2-M) (Genset).23 The reaction
started with denaturation at 94°C for 5 min;
proceeded with 25 cycles of amplification at
94°C for 30 sec; at 57°C for 30 sec; at 72°C for
30  sec;  and  terminated  at  72°C  for  10  min.
Amplification  products  were  run  in  a  3%
agarose  gel,  stained  with  ethidium  bromide
and visualized after UV. The reaction condi-
tions were chosen so that none of the RNAs
analyzed reached a plateau at the end of the
amplification procedure, i.e. when amplifica-
tion proceeds exponentially at a constant effi-
ciency and the yield of the RT-PCR product is
proportional to the starting amount of the tem-
plate. Therefore, no product of MDR1 amplifi-
cation was seen in CML samples with normal
level of MDR1 gene expression, as well as in
samples from healthy donors used as negative
controls. In these cases the only visible product
of PCR was the intensive band corresponding
to  β2-M RNA  (MDR1-negative).  All  samples
that showed clearly visible product of MDR1
amplification with intensity lower, equivalent
or higher than β2-M product were considered
as MDR1-positive (i.e. with over-expression).
RNA from healthy volunteers was included as a
negative control, and RNA from an acute lym-
phoblastic leukaemia (FAB L3 subtype) patient
with manifested drug resistance and immuno-
logically confirmed high level of P-gp expres-
sion was used as a positive control.
Strict  precautions  to  avoid  carryover  con-
taminations were followed as recommended by
Kwok & Higushi.24
Statistical analysis
The type of BCR-ABL transcripts and MDR1
gene expression status were analyzed in correla-
tion to age, sex and peripheral blood parameters
(hemoglobin, leukocyte count and platelets). All
statistical  analyses  were  performed  using  the
SPSS 9.0 software. The Wilcoxon Mann–Whitney
test was used to compare the distributions of
numerical-valued  variables  between  patients
with b3a2 and with b2a2 transcripts, as well as
between subgroups of patients with normal and
with elevated levels of MDR1 gene expression.
Univariate differences between categorical vari-
ables subsets were evaluated by Fisher’s exact
test. P-values of 0.05 or less were considered to
be of statistical significance. 
Results
In this study we analyzed the type of BCR-
ABL transcripts and MDR1 gene expression in
98 untreated adult patients with chronic phase
CML and correlated the findings with clinical,
hematological and molecular data (Table 1).
Types of BCR-ABL transcripts in
correlation to basic patients’ char-
acteristics at presentation
RT-PCR was used to confirm the diagnosis of
CML by detection of fusion BCR-ABL gene, and
to reveal the type of transcripts depending on
the M-bcrregion breakpoint location. All studied
patients  were  found  to  be  BCR-ABL positive.
Fifty-three of them expressed b3a2 transcripts
[54%],  whereas  forty-four  of  the  remaining
cases were positive for b2a2 transcripts [45%].
Co-expression of both types of transcripts (b2a2
(+) b3a2) was observed in one patient [1%],
who  was  excluded  from  further  analysis.  All
patients were analyzed to determine the rela-
tionship between the type of transcripts and the
presenting features at diagnosis including age,
sex, white blood cells (WBC) count, platelets
and  hemoglobin  (Hb)  concentration.  The
platelets count was statistically higher in the
subgroup  of  patients  expressing  b3a2,  than
those with b2a2 transcript (791.3±441.3ﾥ109/L
vs. 440.4± 283.4ﾥ109/L; P=0.007). The remain-
ing variables were not significantly different in
both groups (b2a2 and b3a2) (P>0.05). (Table
2).
MDR1 expression in correlation to
basic patients’ characteristics at
presentation
The pattern of MDR1 amplification in CML
Article
Table 1. Basic demographic and hemato-
logical features of patients included in the
study.
Total number of patients [n=] 98
Gender
Males [n=] 59 [60%]
Females [n=]  39 [40%]
Age
Mean ± SD [years] 50.5±14.12
WBC
Mean ± SD [ﾥ109/L] 125.2±90.4
Platelets
Mean ± SD [ﾥ109/L] 615.8±406.3
Hemoglobin
Mean ± SD [g/L] 111.7±27.0[Hematology Reports 2011; 3:e3]
patients varied considerably from case to case
with a different intensity of the reaction rang-
ing from negative to strongly positive. RT-PCR
revealed moderate or strong positive reaction,
corresponding  to  over-expression  of  MDR1
gene  [MDR1(+)],  in  48  out  of  97  patients
(49.5%).  No  product  of  MDR1 amplification,
corresponding  to  a  normal  level  of  MDR1
expression  [MDR1(–)],  was  seen  in  the
remaining 49 patients (50.5%).
The  mean  WBC  count  was  significantly
lower in MDR1(+) patients [105.5± 79.8ﾥ109/L
vs. 143.6±96.5 ﾥ109/L (P=0.047)in MDR1(–)].
In addition, MDR1 gene over-expression was
significantly more frequent in elderly patients
with age >60 years - 71% (24/34), compared to
that  in  younger  patients  -  38%  (24/63)
(P=0.008), although, the mean age did not dif-
fer between the MDR1(+) and MDR1– patients
(P>0.05). No significant differences in regard
to  sex,  type  of  BCR-ABL transcripts,  platelet
count and hemoglobin concentration between
the two groups of patients expressing either
normal  or  elevated  MDR1 levels  were  found
(P>0.05) (Table 3). 
The impact of MDR1 status 
of patients on the association
between the types of BCR-ABL
transcripts with basic characteristics
at the presentation
In order to determine the impact of MDR1
status of patients on the association of the type
of transcripts with clinical and biological char-
acteristics,  both  groups  were  additionally
divided into subgroups with normal and elevat-
ed  MDR1 levels.  The  analysis  of  the  b3a2
patients revealed a lower mean WBC count in
MDR1(+)  cases  compared  to  the  respective
value  in  MDR1(–) patients  [85.4±61.2ﾥ109/L
vs. 150.8±86.6 ﾥ109/L(–)(P=0.004)]. However,
no differences in the patients’ characteristics
were found in the b2a2 group according to the
MDR1 status. Appling the same approach by
stratifying the patients according to the MDR1
status, no significant differences in patients’
characteristics  were  observed  between  b3a2
and  b2a2  cases  with  normal  MDR1 levels
(Table 4). In contrast, within the group with
MDR1 over-expression, the b3a2-positve cases
were characterized with a significantly higher
platelets  count  (P=0.006)  and  lower  WBC
count  (P=0.004)  compared  to  b2a2-positive
patients (Table 4)
Discussion
Data  concerning  the  association  between
the  type  of  BCR-ABL transcripts  and  CML
patient  characteristics  remain  contradictory.
Therefore, we compared the main clinical fea-
Articles
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Table 2. Association between clinical and laboratory data and the type of fusion BCR-
ABL transcripts for the 97 chronic myeloid leukemia patients.
Parameter BCR-ABL transcripts P
b3a2  b2a2
Patients [n=] 53 [55%] 44 [45%]
Age
Mean ± SD [years]  51.0 ±13.7 49.9± 4.8 NS
Gender
Males [n=] 28 [53%] 25 [47%] NS
Females [n=] 31 [70%] 13 [30%]
WBC
Mean ± SD [ﾥ109/L] 119.5±81.7 132.4±100.8 NS
Platelets
Mean ± SD [ﾥ109/L] 791.3±441.3 440.4±283.4 0.007
Hemoglobin
Mean ± SD [g/L] 116.0±19.1 107.9±32.5 NS 
Table 3. Clinical parameters at diagnosis of CML patients in chronic phase expressing
normal and elevated levels of MDR1 gene.
Parameter MDR1(+) patients MDR1(–) patients P
Patients [n=] 48 [49.5%] 49 [50.5%]
Age
Mean ± SD [years]  52.4±15.4 48.7±12.6 NS
Patients
>60 years  [n=] 24/34 [71%]  10/34 [29%] 0.008
<60 years  [n=] 24/63 [38%] 39/63 [62%]
Gender
Males [n=] 27 [56%] 32 [65%] NS
Females  [n=] 21 [44%] 17 [35%]
BCR-ABL transcripts
b3a2 [n=] 25 [52%] 28 [57%] NS
b2a2 [n=]               23 [48%] 21 [43%]
WBC
Mean ± SD [ﾥ109/L] 105.5±79.8 143.6±96.5 0.047
Platelets
Mean ± SD [ﾥ109/L] 647.2±447.8 591.0±381.4 NS
Hemoglobin
Mean ± SD 110.6±38.6 112.4±17.2 NS
Table 4. Clinical and laboratory data of patients with different types of fusion BCR-ABL
transcripts and MDR1 expression.
Parameter MDR1(+) patients P MDR1(-) patients P
b3a2 b2a2 b3a2 b2a2
[n=25] [n=23] [n=28] [n=21]
Age: mean±SD [years] 53.0±15.2 51.6±16.0 NS 49.3±12.1 47.9±13.6 NS
Patients
>55 years  [n=] 12 [48%] 12 [52%] NS 7 [25%] 5 [24%] NS
<55 years  [n=] 13 [52%] 11 [48%] 21 [75%] 16 [76%]
Gender
Males [n=]  11 [44%] 16 [70%] NS 17 [61%] 15 [71%] NS
Females [n=] 14 [56%] 7 [30%] 11 [39%] 6 [29%]
WBC:   85.4±61.2 130±93.9 0.004 150.8±86.6 134.6±109.5NS
mean±SD [ﾥ109/L]
Platelets:  908.7±470.1 472.9±356.10.006 727.3±434.0 403.8±189.1NS
mean±SD[ﾥ109/L]
Hemoglobin:  123.5±18.6 103.1±46.2 NS 112.7±19.4 112.1±15.6 NS
mean±SD [g/L][page 8] [Hematology Reports 2011; 3:e3]
tures of BCR-ABL-positive CML patients to the
type  of  transcripts.  The  only  variable,  that
showed significant difference between the two
groups, was the platelet count, which was sig-
nificantly  higher  in  patients  who  expressed
b3a2, providing additional evidence that b3a2
transcripts seem to be associated with a high-
er thrombopoietic activity in CML.7-9
In addition, the most interesting finding in
our study was that the significant correlation
between the elevated platelets count and b3a2
transcripts  compared  to  b2a2  was  restricted
only to the subgroup of patients with MDR1
over-expression,  Moreover,  the  MDR1 over-
expression status outlined a significant asso-
ciation between the WBC count and the type of
transcripts as we observed  lower counts in the
b3a2-positive cases compared to b2a2. No sim-
ilar differences were found between b3a2- and
b2a2-positive  patients  within  the  subgroup
with normal MDR1 levels.
A possible explanation is that the significant
differences in the platelets and WBC count in
patients with b3a2 and b2a2 transcripts only in
patients with MDR1 over-expression reflect a
preferential activation of a common specific
signaling cascade in the b3a2- positive cases,
which is not active in the remaining patients.
This might be related to variations in the level
of BCR-ABL transcripts, since a dose-depend-
ent hierarchy of BCR-ABL induced activation
of  signaling  pathways  and  biological  effects
exists.25 Moreover, it has been reported that
b3a2 transcripts may affect the thrombopoietic
activity in CML also in a dose-response man-
ner.7 Alternatively,  it  might  be  also  possible
that MDR1 over-expression due to additional
molecular abnormalities might interfere with
differences in the structure of two p210Bcr-Abl
proteins preferentially promoting the interac-
tion of b3a2 with the cytoskeleton of megakary-
ocytes8 resulting in the particular CML pheno-
type presented by thrombocytosis and relative-
ly lower leukocytosis. 
However, this hypothesis is only speculative
and needs to be confirmed because the precise
molecular mechanisms that underline an ele-
vated  MDR1 expression  in  untreated  CML
patients  are  still  unknown.  In  general,  data
concerning MDR1 expression in CML are still
insufficient and contradictory. Our study pro-
vides some interesting information in regard
to the incidence of MDR1 over-expression and
the related patients’ characteristics.  We found
elevated  levels  in  approximately  50%  of
untreated patients. This result was in agree-
ment with the data, reported earlier by Giles et
al. (1999) and Weide et al. (1990), who using
alternative  methods  revealed  high  levels  of
MDR1/P-gp expression in 57% and 41% of CML
cases, respectively.14,26In our study, there were
no differences in the prevalence of the differ-
ent types of transcripts, as well as in the gen-
der,  platelets  count  and  hemoglobin  level
between patients with normal and elevated lev-
els of MDR1. However, the incidence of MDR1
gene  over-expression  was  significantly  more
frequent  among  the  older  patients.  Similar
results  were  observed  not  only  in  chronic
phase  CML  patients,14 but  also  in  acute
leukemias.27,28 Moreover,  an  age-related
increase  of  P-gp  expression  was  found  on
peripheral blood cells of healthy individuals.29
All these data suggest that common biological
factors may contribute to the drug resistance
in the elderly. 
Additionally,  we  and  others14 found  that
MDR1 over-expression in CML was associated
with  a  lower  WBC  count  compared  to  the
patients  with  normal  MDR1 levels.
Interestingly, in acute leukemias, the MDR1
over-expression has been reported to be asso-
ciated with hyperleukocytosis, both in AML27
and ALL.28 To our knowledge, no explanation
for these differences has been reported so far. 
Some observations suggest that the MDR1
gene over-expression in CML might be one of
multiple  cellular  alterations  caused  by  the
p210BCR-ABL.  Physiologically,  the  regulation  of
MDR1 gene expression involves various signal-
ing pathways (i.e. p53, SP1, NF-Y, AP-1, NF-kB,
C/EBP and RAS).30 A key role in this process
plays Jun NH2-terminal protein kinase (JNK),
which  in  response  to  stress-signals  activates
the  heterodimeric  AP-1  transcription  factor,
which in turn interacts with the MDR1 gene
promoters and enhances transcription.31 Given
that it has been shown that p210BCR-ABL may
activate  most  of  these  pathways,1  including
JNK,32 it seems possible that the hybrid onco-
proteins may also affect MDR1 expression in
this manner.31This hypothesis is also supported
by the observation that transduction of normal
cells with b3a2 cDNA leads to upregulation of
the expression of P-glycoprotein, the product of
the MDR1 gene.33 Alternatively, the differences
in the MDR1 expression in CML patients might
be related to defects in the methylation machin-
ery as a distinct molecular pathway leading to
malignant transformation34 or might be a ran-
dom  event  associated  with  nucleotide  and/or
haplotype  variants  of  the  MDR1 gene,  which
seems to be important for interindividual differ-
ences of its expression.35-38
In conclusion, our preliminary results indi-
cate that the type of BCR-ABL transcripts cor-
relates with the hematological parameters of
CML patients, however only in the subgroup of
patients  characterized  by  over-expression  of
MDR1 gene. Further studies need to elucidate
the molecular events underlying the relation-
ship between the type of BCR-ABL transcripts
and expression of MDR1 gene in CML. 
References
1. Quintás-Cardama  A,  Cortes  J.  Molecular
biology  of  bcr-abl1-positive  chronic
myeloid  leukemia.  Blood  2009;113:1619-
30.
2. de Lemos JA, de Oliveira CM, Scerni AC, et
al. Differential molecular response of the
transcripts  B2A2  and  B3A2  to  imatinib
mesylate  in  chronic  myeloid  leukemia.
Genet Mol Res 2005;4:803-11.
3. Lucas CM, Harris RJ, Giannoudis A, et al.
Chronic  myeloid  leukemia  patients  with
the e13a2 BCR-ABL fusion transcript have
inferior responses to imatinib compared to
patients  with  the  e14a2  transcript.
Haematologica 2009;94:1362-7.
4. Sharma  P,  Kumar  L,  Mohanty  S,
Kochupillai V. Response to Imatinib mesy-
late in chronic myeloid leukemia patients
with variant BCR-ABL fusion transcripts.
Ann Hematol. 2010;89:241-7.
5. Mondal BC, Bandyopadhyay A, Majumdar
S,  et  al.  Molecular  profiling  of  chronic
myeloid leukemia in eastern India. Am J
Hematol 2006;81:845-9.
6. Adler  R,  Viehmann  S,  Kuhlisch  E,  et  al.
Correlation of BCR/ABL transcript variants
with patients' characteristics in childhood
chronic  myeloid  leukaemia.  Eur  J
Haematol 2009;82:112-8.
7. Inokuchi K, Inoue T, Tojo A, et al. A possi-
ble correlation between the type of bcr-abl
hybrid messenger RNA and platelet count
in Philadelphia-positive chronic myeloge-
nous leukemia.Blood 1991;78:3125-7.
8. Perego RA, Costantini M, Cornacchini G,
et al. The possible influences of B2A2 and
B3A2 BCR/ABL protein structure on throm-
bopoiesis  in  chronic  myeloid  leukaemia.
Eur J Cancer 2000;36:1395-401.
9. Verschraegen CF, Kantarjian HM, Hirsch-
Ginsberg C, et al. The breakpoint cluster
region site in patients with Philadelphia
chromosome-positive  chronic  myeloge-
nous  leukemia.  Clinical,  laboratory,  and
prognostic  correlations.  Cancer  1995;76:
992-7.
10. Rozman C, Urbano-Ispizua A, Cervantes F,
et al. Analysis of the clinical relevance of
the breakpoint location within M-BCR and
the  type  of  chimeric  mRNA  in  chronic
myelogenous leukemia. Leukemia 1995;9:
1104-7.
11. Opalka B, Wandl UB, Kloke O, et al. No
correlation between site of breakpoint in
the  BCR gene  and  platelet  counts  in
Philadelphia  chromosome-positive  CML.
Leuk Res 1992;16:937-9.
12. Melo J. The diversity of BCR-ABL fusion
proteins  and  their  relationship  to
leukemia phenotype. Blood 1996;88:2375-
84.
Article[Hematology Reports 2011; 3:e3]
13. Shepherd P, Suffolk R, Halsey J, Allan N.
Analysis of molecular breakpoint and m-
RNA transcripts in a prospective random-
ized trial of interferon in chronic myeloid
leukaemia:  no  correlation  with  clinical
features, cytogenetic response, duration of
chronic phase, or survival. Br J Haematol
1995;89:546-54.
14. Giles FJ, Kantarjian HM, Cortes J, et al.
Multidrug  resistance  protein  expression
in chronic myeloid leukemia: associations
and significance. Cancer 1999;86:805-13.
15. Leonard GD, Fojo T, Bates SE. The role of
ABC  transporters  in  clinical  practice.
Oncologist 2003;8:411-24.
16. Nüssler V, Pelka-Fleischer R, Zwierzina H,
et  al.  Clinical  importance  of  P-glycopro-
tein-related  resistance  in  leukemia  and
myelodysplastic  syndromes--first  experi-
ence  with  their  reversal.  Ann  Hematol
1994;69:S25-9.
17. Sato H, Gottesman MM, Goldstein LJ, et al.
Expression  of  the  multidrug  resistance
gene  in  myeloid  leukemias.  Leuk  Res
1990;14:11-21.
18. Stavrovskaya A, Turkina A, Sedyakhina N,
et  al.  Prognostic  value  of  P-glycoprotein
and leukocyte differentiation antigens in
chronic  myeloid  leukemia.  Leuk
Lymphoma 1998;28:469-82. 
19. Michelutti A, Michieli M, Damiani D, et al.
Overexpression of MDR-related p170 gly-
coprotein  in  chronic  myeloid  leukemia.
Haematologica 1994;79:200-4.
20. Herweijer H, Sonneveld P, Baas F, Nooter
K.Expression of mdr1 and mdr3 multidrug-
resistance  genes  in  human  acute  and
chronic  leukemias  and  association  with
stimulation  of  drug  accumulation  by
cyclosporine.  J  Natl  Cancer  Inst
1990;82:1133-40.
21. Isotalo  PA,  Wells  GA,  Donnelly  JG.
Neonatal and fetal methylenetetrahydrofo-
late reductase genetic polymorphisms: an
examination of C677T and A1298C muta-
tions. Am J Hum Genet 2000;67:986-90.
22. van Dongen JJ, Macintyre EA, Gabert JA, et
al. Standardized RT-PCR analysis of fusion
gene transcripts from chromosome aber-
rations in acute leukemia for detection of
minimal  residual  disease.  Report  of  the
BIOMED-1 Concerted Action: investigation
of  minimal  residual  disease  in  acute
leukemia. Leukemia. 1999;13:1901-28.
23. Veelken  H,  Licht  T,  Lais  A,  et  al.  Drug
resistance  of  secondary  acute  myeloid
leukemia with megakaryoblastic features
and p190 BCR-ABL rearrangement. Leuk
Res 1998;22:1021-7.
24. Kwok  S,  Higuchi  R.  Avoiding  false  posi-
tives with PCR. Nature 1989; 18;339:237-8.
25. Cambier  N,  Chopra  R,  Strasser  A,  et  al.
BCR-ABL  activates  pathways  mediating
cytokine  independence  and  protection
against apoptosis in murine hematopoiet-
ic  cells  in  a  dose-dependent  manner.
Oncogene 1998;16:335-48.
26. Weide R, Dowding C, Paulsen W, Goldman
J. The role of the MDR-1/P-170 mechanism
in  the  development  of  multidrug  resist-
ance  in  chronic  myeloid  leukemia.
Leukemia 1990;4:695-9.
27. Leith  CP,  Kopecky  KJ,  Chen  IM,  et  al.
Frequency and clinical significance of the
expression  of  the  multidrug  resistance
proteins MDR1/P-glycoprotein, MRP1, and
LRP  in  acute  myeloid  leukemia:  a
Southwest  Oncology  Group  Study.  Blood
1999;94:1086-99.
28. Damiani D, Michelutti A, Michieli M, et al.
P-glycoprotein,  lung  resistance-related
protein and multidrug resistance-associat-
ed  protein  in  de  novo  adult  acute  lym-
phoblastic  leukaemia.  Br  J  Haematol
2002;116:519-27.
29. Svoboda-Beusan I, Kusec R, Bendelja K, et
al. The relevance of multidrug resistance-
associated  P-glycoprotein  expression  in
the treatment response of B-cell chronic
lymphocytic  leukemia.Haematologica
2000;85:1261-7. 
30. Schaich M, Illmer T. Mdr1 gene expression
and mutations in Ras proto-oncogenes in
acute myeloid leukemia. Leuk Lymphoma.
2002;43:1345-54.
31. Sukhai M, Piquette-Miller M. Regulation
of the multidrug resistance genes by stress
signals.  J Pharm Pharm Sci 2000;3:268-80.
32. Raitano  AB,  Halpern  JR,  Hambuch  TM,
Sawyers CL. The Bcr-Abl leukemia onco-
gene  activates  Jun  kinase  and  requires
Jun for transformation. Proc Natl Acad Sci
U S A 1995;92:11746-50.
33. Fan  E,  Hu  Y,  Zhao  C.  Human  stem  cell
model  to  study  signal  transduction  and
molecular regulation mechanisms in CML.
Chin Med J (Engl) 2001;114:680-4.
34. Garcia-Manero G, Daniel J, Smith TL, et al.
DNA  methylation  of  multiple  promoter-
associated CpG islands in adult acute lym-
phocytic  leukemia.  Clin  Cancer  Res
2002;8:2217-24.
35. Takane Takane H, Kobayashi D, Hirota T,
et al. Haplotype-oriented genetic analysis
and  functional  assessment  of  promoter
variants  in  the  MDR1  (ABCB1)  gene.  J
Pharmacol Exp Ther 2004;311:1179-87. 
36. Illmer T, Schuler US, Thiede C, et al. MDR1
gene  polymorphisms  affect  therapy  out-
come in acute myeloid leukemia patients.
Cancer Res 2002;62:4955-62.
37. Taheri  M,  Mahjoubi  F,  Omranipour  R.
Effect  of  MDR1  polymorphism  on  mul-
tidrug resistance expression in breast can-
cer patients. Genet Mol Res 2010;9:34-40.
38. Illmer T, Schaich M, Platzbecker U, et al. P-
glycoprotein-mediated  drug  efflux  is  a
resistance  mechanism  of  chronic  myel-
ogenous leukemia cells to treatment with
imatinib mesylate. Leukemia 2004;18:401-
8.
Article
[page 9]